Clinical study on efficiency and safety of fondaparinux in the elder patients with acute ST elevated myocardial infarction
HE Hua
HAN Fu-sheng
JIA Ping
WEN Bo
Abstract：Objective To explore the efficiency and safety of Fondaparinux in the elder patients with acute ST elevated myocardial infarction(STEMI).Methods All 169 cases (＞65 years)with acute STEMI were selected and percutaneous coronary intervention (PCI)were performed on all cases.All 169 cases were after PCI.The patients in observation group were given fondaparinux,2.5 mg,and patients in control group were given enoxaparin,100AxaIU/kg,q12h after persistent 48-hour intravenous injection of heparin.The follow-up was performed one month after discharge.Paramenters of blood rountine,urine routine,biochemical analysis,electrocardiography,echocardiography,major adverse cardiovascular events(MACE)and adverse effects in both groups were recorded.Results There were no cardiogenic death and non-fatal infarction in both groups,but there were 5 unstable angina pectoris(UAP)in observation group and 4 cases with UAP in control group.There was no difference in blood rountine,urine routine,biochemical analysis,electrocardiography and echocardiography in both groups.The incidence of mini-bleeding events was 3.5％ (3/85)in observation group,which was lower than that [7.1％ (6/84)] in control group,but there was no significant difference(P ＞ 0.05).Conclusion Fondaparinux used in the elder patients with acute STEMI is effective and safe,and fondaparinux has potential advantage on hemorrhage risk compared with enoxaparin.
Keywords：Myocardial infarctionacuteST elevatedFondaparinuxEnoxaparin
Publication Date：2012-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)